Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
This study evaluated the safety and effectiveness of Mexidol for people with ADHD.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Mexidol for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Yekaterinburg and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 333
- Sponsor
- Pharmasoft
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Russia
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT06854601
- Official title
Show the full official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial in Three Parallel Groups to Evaluate the Effectiveness and Safety of Mexidol® Film-coated Tablets, 125 mg (LLC 'NPK PHARMASOFT', Russia) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years With Various Dosing Regimens (MEGA).
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Yekaterinburg, Russia · Kazan', Russia · Krasnodar, Russia
9 more locations
- Moscow, Russia
- Nizhny Novgorod, Russia
- Orenburg, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tver', Russia
- Tyumen, Russia
- Ulyanovsk, Russia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Mexidol for people with ADHD.
Who is behind this study?
The study sponsor is Pharmasoft.
Did this study involve medication?
Yes. The study involved medication, including Mexidol, Placebo and Mexidol + Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
